Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 5/20 | 0.48 |
| ▸ | ABL1 | P00519 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 2/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.48 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 7/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4091656 | 0.91 | MAPK14 (0.69) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4081423 | 0.83 | SRC (0.70) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4092906 | 0.82 | SRC (0.62) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4091873 | 0.81 | MAPK14 (0.81) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL5380711 | 0.80 | MAPK14 (0.56) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4088020 | 0.76 | MAPK14 (0.75) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4085454 | 0.74 | MAPK14 (0.82) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4087842 | 0.73 | MAPK14 (0.79) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4096411 | 0.73 | SRC (0.54) | MAPK14BRAFABL1RAF1LYN | |
| SCHEMBL4098327 | 0.73 | MAPK14 (0.81) | MAPK14BRAFABL1RAF1LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | MOSS NEIL | 2007-07-05 | — | — | US | disclosed |
| US-7211575-B2 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1690854-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7026476-B2 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-7019006-B2 | Modulating release of inflammatory cytokines by administering, e.g., a 1-(5-tert-butyl-2-methyl-phenyl)-3-(6-((3-methoxy-propyl)-methylaminopyridin-3-yl)phthalen-1-yl) urea or thiourea; treating a neutrophil-mediated disease | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1466906-A1 | Heterocyclic urea and related compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1427412-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1381594-A1 | UREA COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-6660732-B2 | Compounds useful as anti-inflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030225077-A1 | Intermediate arylamine compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6656933-B2 | Novel compounds which inhibit production of cytokines involved in inflammatory processes | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-02 | — | — | US | disclosed |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2003022273-A1 | METHODS OF TREATING CYTOKINE MEDIATED DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002083642-A1 | COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-06-27 | — | — | US | disclosed |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | BETAGERI RAJASHEHAR (US) | 2002-05-09 | — | — | US | disclosed |
| US-6358945-B1 | CYTOKINE, TUMOR NECROSIS FACTOR, AND INTERLEUKIN INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155724-A1 | Methods of Treating Cytokine Mediated Diseases | TNF, IL2, IL1B | MAPK14 922/4885BRAF 2434/4885ABL1 2843/4885 |
| US-20030225077-A1 | Intermediate arylamine compounds | AHR, AADAC, NAT1 | MAPK14 2681/4885BRAF 2563/4885ABL1 310/4885 |
| US-20020082256-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | MAPK14 2740/4885BRAF 3611/4885ABL1 3659/4885 |
| US-20030060455-A1 | Methods of treating cytokine mediated diseases | TNF, IL2, IL1B | MAPK14 922/4885BRAF 2434/4885ABL1 2843/4885 |
| US-20020055507-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | MAPK14 2740/4885BRAF 3611/4885ABL1 3659/4885 |
| US-20040019038-A1 | Compounds useful as anti-inflammatory agents | NFKBIA, TNF, MPO | MAPK14 2740/4885BRAF 3611/4885ABL1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.